Research graph
References from Racial/Ethnic Disparities in Risk of Second Primary Malignancies among Diffuse Large B-Cell Lymphoma Survivors. Local targets link to admitted publications; unresolved targets remain external evidence.
Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population
10.1080/10428194.2020.1839656 · 2021 · External reference
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era
10.1111/bjh.14638 · 2017 · External reference
Second primary malignancies in diffuse large B-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy
10.1016/j.adro.2022.101035 · 2022 · External reference
Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors
10.1007/s00277-023-05095-8 · 2023 · External reference
Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype
10.1200/jco.2010.29.1112 · 2010 · External reference
Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis
10.1002/cncr.32513 · 2020 · External reference
Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
10.1182/bloodadvances.2019030924 · 2019 · External reference
Second primary malignancy in diffuse large B cell lymphoma (DLBCL)
10.1182/blood.v124.21.2606.2606 · 2014 · External reference
Cyclophosphamide-associated bladder cancers and considerations for survivorship care: a systematic review
10.1016/j.urolonc.2021.05.017 · 2021 · External reference
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: recent advances and emerging therapies
10.1186/s13045-025-01702-5 · 2025 · External reference
Sexual practices, sexually transmitted diseases, and the incidence of anal cancer
10.1056/nejm198710153171601 · 1987 · External reference
The role of HIV in race-based differences in diffuse large B-cell lymphoma(DLBCL) treatment and outcomes
10.1182/blood.v128.22.1189.1189 · 2016 · External reference
Doxorubicin cardiotoxicity in African Americans
2004 · External reference
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients
10.1007/s00280-011-1815-5 · 2012 · External reference
Influence of genetic variation of GST, CYP, and ABC on the safety and efficacy of cyclophosphamide-based therapy
10.1111/cts.70301 · 2025 · External reference
Pharmacogenetics as a future tool to risk-stratify breast cancer patients according to chemotoxicity potential from the doxorubicin hydrochloride and cyclophosphamide (AC) regimen
10.3390/ph18040539 · 2025 · External reference
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
10.1056/nejmoa1409405 · 2014 · External reference
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
10.1038/s41588-020-00710-0 · 2020 · External reference
Inherited causes of clonal haematopoiesis in 97,691 whole genomes
10.1038/s41586-020-2819-2 · 2020 · External reference
Differences in the mutational landscape of clonal hematopoiesis of indeterminate potential among races and between male and female patients with cancer
10.1016/j.exphem.2024.104271 · 2024 · External reference
